The Case For Disappearing Stents: More Positive Data For Abbott’s Absorb BVS
This article was originally published in The Gray Sheet
This year’s Transcatheter Cardiovascular Therapeutics meeting featured several presentations of favorable new data on Abbott’s Absorb bioresorbable vascular scaffold. The company is optimistic that it will be able to complete a PMA application to FDA for the disappearing stent by the end of 2015.
You may also be interested in...
The firm's FDA submission for the first-in-class bioresorbable vascular scaffold was completed in the second quarter, a spokesman said. That appears to be ahead of a prior estimate to submit by the end of 2015.
Product news from Silk Road Medical, EnteroMedics, St. Jude, Tandem Diabetes and Abbott.
Bioresorbable coronary scaffolds could transform the coronary stenting market once they become widely available. But although there are more than a dozen companies developing these promising devices, there are still a number of unanswered questions – chief among them, how effectively they will compete against existing and upcoming next-generation durable stents, and how much of a price premium bioresorbable devices will be able to command.